𝐔𝐊 𝐁𝐢𝐨𝐭𝐞𝐜𝐡: This week our UK based correspondent Amy Brown visited Stevenage Bioscience Catalyst, a key life sciences research campus in the UK. Entrepreneurship and Business Development Director Marco Delise, PhD describes the facilities available at SBC and the types of companies that are housed here. Full video: https://lnkd.in/gi3thjWZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies. Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRO to advance its lead program for gout into the clinic to proof of concept, as well as expand the company’s pipeline. Full video: https://lnkd.in/gP_i-Phd BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Click Therapeutics, Inc. founder David Benshoof Klein on the digital therapeutics space and the regulatory opportunity for combining medicines with apps. He describes how the digital therapeutics space works and highlights Click's programs and partnerships with large pharmaceutical companies. Full video: https://lnkd.in/gWgGqYze BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐇𝐒𝐁𝐂 𝟏𝐇 𝟐𝟎𝟐𝟒 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 Yesterday, HSBC Innovation Banking's Jonathan Norris published his semi-annual report that digs into venture trends. We spoke with him about some of the highlights. Download the report: https://lnkd.in/ggqMVkCH #sponsored
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Stevenage, UK based Antikor Biopharma Ltd is developing ADCs using 'OptiLinked' smaller antibody fragments. CEO Mahendra Deonarain describes the potential advantages of this approach over traditional ADCs and talks about the company's lead program that targets CMET. Full video: https://lnkd.in/ggAdEZRf BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Stevenage, UK based Autifony Therapeutics has been building a CNS pipeline from its expertise in ion channel drug discovery. Founder & CEO Charles Large describes the scientific foundation Autifony has built in ion channel science and how the company is leveraging it against Fragile X syndrome, orphan epilepsies, and more. Full video: https://lnkd.in/g_jQVE4t BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐇𝐒𝐁𝐂 𝟏𝐇 𝟐𝟎𝟐𝟒 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 Jonathan Norris has published his semi-annual venture healthcare report today. The report places the industry under a microscope, sector-by-sector, for in-depth analysis on key trends. Download the report: https://lnkd.in/ggqMVkCH #sponsored
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Stevenage, UK based Spur Therapeutics is readying to take its gene therapy for Gaucher disease into phase 3. CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has given the company confidence to plan to initiate a phase 3 trial next year. Full video: https://lnkd.in/grQ6tVFs BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Daiichi Sankyo US's global head of R&D Ken Takeshita talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square. From a partnering event being held at MassBio's HQ, he describes Daiichi's targets under development beyond HER2 and TROP2, plus what the company is looking at outside of ADCs. Full video: https://lnkd.in/ekautr4J BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent